ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:00 p.m. ET in New York City. Investors interested in arranging a meeting ...

Core Insights - Jazz Pharmaceuticals plc will participate in the BofA Securities 2025 Healthcare Conference on May 14, 2025 [1] - An audio webcast of the fireside chat will be available on the company's investor website and archived for 30 days [2] Company Overview - Jazz Pharmaceuticals is a global biopharma company focused on developing life-changing medicines for serious diseases with limited therapeutic options [3] - The company has a diverse portfolio, including leading therapies for sleep disorders, epilepsy, and a growing range of cancer treatments [3] - Jazz is headquartered in Dublin, Ireland, with research and development facilities and manufacturing sites in multiple countries [3]